DermiSphere™ hDRT
Full-thickness skin loss (e.g., traumatic wounds, surgical excisions, burns)
Pre-clinicalActive
Key Facts
Indication
Full-thickness skin loss (e.g., traumatic wounds, surgical excisions, burns)
Phase
Pre-clinical
Status
Active
Company
About Fesarius Therapeutics
Fesarius Therapeutics is an early-stage biotech developing a first-of-its-kind hydrogel dermal regeneration template (hDRT) called DermiSphere™. The technology, based on a dual-density collagen hydrogel architecture, is designed to accelerate and improve the healing of severe wounds by promoting rapid cellular invasion and vascularization. Currently in the pre-clinical stage, the company is positioning its product as a significant innovation in a wound care market that has seen limited advancement. Fesarius operates as a private, pre-revenue company seeking to address a substantial unmet need in reconstructive surgery and chronic wound management.
View full company profile